C Zamarrón1, F Maceiras, A Mera, J J Gómez-Reino. 1. The Sleep Unit of the Respiratory Service, Hospital Clinico Universitario and Medical School, Universidad de Santiago de Compostela, Spain.
Abstract
OBJECTIVE: To assess the benefit of the first infliximab infusion on sleep disturbances in patients with RA Material and methods: Evaluation of RA activity, sleepiness (Epworth scale and multiple sleep latency test), alertness (steer clear test), and sleep structure (polysomnography) were conducted before and after the first infusion of infliximab in six female patients with RA. RESULTS: The day after the first infliximab infusion, the mean (SD) number of tender (20 (2.4)) or swollen (15.3 (2)) joints and the morning stiffness (140 (61.9) min) had not changed. There were significant improvements in the median number of total sleep stage transitions per hour (median (IR) before v after infusion: 20.5 (43) v 7.5 (6); Wilcoxon paired test, p = 0.014), median percentage of phase I+II (83.5 (8) v 54.5 (24); p = 0.023), percentage of REM stages (2 (10) v 11.5 (8); p = 0.014), median percentage sleep efficiency (44 (22) v 75 (18); p = 0.014), median sleep latency (77.5 (150) v 25.5 (23) min; p = 0.023), and median number of hits in the steer clear test (48.5 (86) v 6 (45); p = 0.023). Neither objective nor subjective daytime sleepiness was noted. One obese patient had obstructive sleep apnoea syndrome. CONCLUSIONS: Sleep and the alertness disturbances in RA improve with infliximab treatment. Improvement appears unrelated to joint discomfort amelioration but suggests a central effect through inhibition of circulating TNFalpha levels.
OBJECTIVE: To assess the benefit of the first infliximab infusion on sleep disturbances in patients with RA Material and methods: Evaluation of RA activity, sleepiness (Epworth scale and multiple sleep latency test), alertness (steer clear test), and sleep structure (polysomnography) were conducted before and after the first infusion of infliximab in six female patients with RA. RESULTS: The day after the first infliximab infusion, the mean (SD) number of tender (20 (2.4)) or swollen (15.3 (2)) joints and the morning stiffness (140 (61.9) min) had not changed. There were significant improvements in the median number of total sleep stage transitions per hour (median (IR) before v after infusion: 20.5 (43) v 7.5 (6); Wilcoxon paired test, p = 0.014), median percentage of phase I+II (83.5 (8) v 54.5 (24); p = 0.023), percentage of REM stages (2 (10) v 11.5 (8); p = 0.014), median percentage sleep efficiency (44 (22) v 75 (18); p = 0.014), median sleep latency (77.5 (150) v 25.5 (23) min; p = 0.023), and median number of hits in the steer clear test (48.5 (86) v 6 (45); p = 0.023). Neither objective nor subjective daytime sleepiness was noted. One obesepatient had obstructive sleep apnoea syndrome. CONCLUSIONS: Sleep and the alertness disturbances in RA improve with infliximab treatment. Improvement appears unrelated to joint discomfort amelioration but suggests a central effect through inhibition of circulating TNFalpha levels.
Authors: Charles L Raison; David B Rye; Bobbi J Woolwine; Gerald J Vogt; Breanne M Bautista; James R Spivey; Andrew H Miller Journal: Biol Psychiatry Date: 2010-05-26 Impact factor: 13.382
Authors: Grant H Louie; Maria G Tektonidou; Alberto J Caban-Martinez; Michael M Ward Journal: Arthritis Care Res (Hoboken) Date: 2011-02 Impact factor: 4.794
Authors: Faith S Luyster; Eileen R Chasens; Mary Chester M Wasko; Jacqueline Dunbar-Jacob Journal: J Clin Sleep Med Date: 2011-02-15 Impact factor: 4.062
Authors: Regina M Taylor-Gjevre; John A Gjevre; Bindu V Nair; Robert P Skomro; Hyun J Lim Journal: Ther Adv Musculoskelet Dis Date: 2011-10 Impact factor: 5.346
Authors: Michael R Irwin; Richard Olmstead; Edwin M Valladares; Elizabeth Crabb Breen; Cindy L Ehlers Journal: Biol Psychiatry Date: 2009-01-29 Impact factor: 13.382